Biobanken – Entwicklung und Struktur

Schlüsselwörter

Biobanken - translationale Forschung - Qualitätsmanagement - Good Scientific Practice - Technologie- und Methodenplattform - Genomik - ELSI

Keywords

biobanks - translational research - quality management - good scientific practice - technology platform - genomics - ELSI

• Literatur

• 1 Baker M. Biorepositories: Building better biobanks. Nature 2012; 486: 141-146
• 2 Bell WC, Sexton KC, Grizzle WE. Organizational issues in providing high-quality human tissues and clinical information for the support of biomedical research. Methods Mol Biol 2010; 576: 1-30
• 3 Bevilacqua G, Bosman F, Dassesse T et al. The role of the pathologist in tissue banking: European Consensus Expert Group Report. Virchows Arch 2010; 456: 449-454
• 4 Chaigneau C, Cabioch T, Beaumont K et al. Serum biobank certification and the establishment of quality controls for biological fluids: examples of serum biomarker stability after temperature variation. Clin Chem Lab Med 2007; 45: 1390-1395
• 5 Cohen MH, Williams G, Johnson JR et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002; 8: 935-942
• 6 Deutscher Ethikrat. Humanbiobanken für die Forschung. http://www.ethikrat.org/presse/pressemitteilungen/2010/pressemitteilung-2010-05 (letzter Zugriff 3.4.2013)
• 7 Grizzle WE, Bell WC, Sexton KC. Issues in collecting, processing and storing human tissues and associated information to support biomedical research. Cancer Biomark 2010; 9: 531-549
• 8 Herpel E, Koleganova N, Schirmacher P. Gewebebank des Nationalen Zentrums für Tumorerkrankungen. Pathologe 2008; 29 (Suppl. 02) 204-209
• 9 Herpel E, Koleganova N, Schreiber B et al. Structural requirements of research tissue banks derived from standardized project surveillance. Virchows Arch 2012; 461: 79-84
• 10 Herpel E, Rocken C, Manke H et al. Quality management and accreditation of research tissue banks: experience of the National Center for Tumor Diseases (NCT) Heidelberg. Virchows Arch 2010; 457: 741-747
• 11 Hewitt R, Hainaut P. Biobanking in a fast moving world: an international perspective. J Natl Cancer Inst Monogr 2011; 42: 50-51
• 12 Hewitt RE. Biobanking: the foundation of personalized medicine. Curr Opin Oncol 2011; 23: 112-119
• 13 Lemieux J, Clemons M, Provencher L et al. The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancers. Curr Oncol 2009; 16: 48-57
• 14 Massett HA, Atkinson NL, Weber D et al. Assessing the need for a standardized cancer HUman Biobank (caHUB): findings from a national survey with cancer researchers. J Natl Cancer Inst Monogr 2011; 42: 8-15
• 15 Morente MM, Alonso S. Current challenges of human tumour banking. Hematol Oncol 2005; 23: 54-56
• 16 Myles JL, Shamanski F, Witte D. The physicians quality reporting initiative: measure development, implementation and current procedural terminology coding. Adv Anat Pathol 2010; 17: 49-52
• 17 Office od Biorepositories and Biospecimen Research. NCI Best Practices for Biospecimen Resources. 2011. http://biospecimens.cancer.gov/bestpractices/ (letzter Zugriff 3.4.2013)
• 18 Simeon-Dubach D, Perren A. Better provenance for biobank samples. Nature 2011; 75: 454-455
• 19 Simm K. The concepts of common good and public interest: from Plato to biobanking. Camb Q Healthc Ethics 2011; 20: 554-562
• 20 Teodorovic I, Isabelle M, Carbone A et al. TuBaFrost 6: virtual microscopy in virtual tumour banking. Eur J Cancer 2006; 42: 3110-3116
• 21 Vaught J, Rogers J, Carolin T et al. Biobankonomics: developing a sustainable business model approach for the formation of a human tissue biobank. J Natl Cancer Inst Monogr 2011; 42: 24-31
• 22 Virchow R. Die Cellularpathologie in ihrer Begründung auf physiologische und pathologische Gewebelehre. Berlin: Verlag von August Hirschwald; 1859
• 23 Von Versen R, Monig HJ, Salai M et al. Quality issues in tissue banking: quality management systems – a review. Cell Tissue Bank 2000; 1: 181-192
• 24 Zatloukal K, Hainaut P. Human tissue biobanks as instruments for drug discovery and development: impact on personalized medicine. Biomark Med 2010; 4: 895-903